Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00328627 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.
A Phase 3 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,554
- Enrollment target
NCT00328627: Completed Phase 3 study, sponsored by Takeda.
NCT00328627 is a Phase 3 study that has completed, run by Takeda. The registered enrollment target is 1,554 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (101% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00328627, a Phase 3 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,554 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of alogliptin, once daily (QD), taken in combination with pioglitazone in adults with type 2 diabetes mellitus.
Primary Outcome
The change from Baseline to Week 26 in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound). The primary analysis compared the groupings (combinations of individual treatment groups) of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone (Pioglitazone Alone).
Interventions
- DRUG Pioglitazone
- DRUG Alogliptin
- DRUG Pioglitazone placebo
- DRUG Alogliptin placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,554 participants |
| Start Date | 2006-05 |
| Est. Completion | 2008-03 |
| Phase | Phase 3 |
What the finished NCT00328627 record still lists
NCT00328627 is an interventional study that assigns participants to a tested intervention. Its 1,554 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (101% higher).
The record links to 0 conditions, and to 4 interventions - of which Pioglitazone is the first listed.
NCT00328627 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00328627 about?
NCT00328627 is a clinical study titled "Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.". The purpose of this study is to evaluate the safety and efficacy of alogliptin, once daily (QD), taken in combination with pioglitazone in adults with type 2 diabetes mellitus.
What is the current status of trial NCT00328627?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,554 participants. The study started on 2006-05. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00328627?
The interventions under investigation include: Pioglitazone (DRUG), Alogliptin (DRUG), Pioglitazone placebo (DRUG), Alogliptin placebo (DRUG).
Who is sponsoring clinical trial NCT00328627?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00328627's enrollment target sits among peer trials
1,554 150th of 2000 higher than 1,851 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02650622 · 1,550 participants
Genetic and Metabolic Disease in Children
- NCT03961945 · 1,550 participants · NA
Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma
- NCT06881069 · 1,560 participants · NA
Reach Through Equitable Implementation in Utah
- NCT06729775 · 1,546 participants · NA
Disentangling the Role of Culture, Life Stage, and Information Design to Facilitate Equity in Data Report Back
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia